Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms
This study is ongoing, but not recruiting participants.
Study NCT00004688 Information provided by FDA Office of Orphan Products Development
First Received: February 24, 2000 Last Updated: June 23, 2005
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Anaplastic Astrocytoma
Anaplastic Oligodendroglioma
Mixed Gliomas
Glioblastoma Multiforme
Recurrent Brain Tumor
Additional conditions recognized in this trial
Astrocytoma
Brain Neoplasms
Glioblastoma
Glioma
Oligodendroglioma
Recurrence
More general conditions related to this trial
Brain Diseases
Central Nervous System Diseases
Central Nervous System Neoplasms
Disease Attributes
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Nervous System Diseases
Nervous System Neoplasms
Neuroectodermal Tumors
Pathologic Processes
Interventions listed in this trial
carmustine
mercaptopurine
streptozocin
Additional drug interventions recognized in this trial
6-Mercaptopurine
More general drug interventions related to this trial
Alkylating Agents
Antibiotics, Antineoplastic
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
FDA Office of Orphan Products Development
Emory University
Back to top of Main Content
